Spexis | Evaluate

Cancer failure prompts Polyphor to give up entirely

Biolinerx could mobilise interest in CXCR4 antagonism

A phase 3 win should remind investors about other clinical-stage CXCR4 antagonists.

August 06, 2019

Share price movers – July 2019

May 13, 2019

Polyphor plunges as lead asset written off

July 02, 2018

June rush drives near-record quarter for biotech flotations

Biotech IPOs raised a huge $2.3bn on Western exchanges in the second-quarter of 2018, as private companies rushed to market ahead of the summer lull.

February 15, 2018

Santhera becomes third group to buy into novel respiratory mechanism

March 23, 2017

Bristol failure makes small dent in CXCR4-blocking approach

March 23, 2012

Therapeutic focus - Eye care products in demand in market dominated by few